采用修订版风险评估策略预测社区起病肺炎抗生素耐药性的相关结局:抗菌药物管理视角
本研究回顾了102例社区起病肺炎患者的病历,比较实施基于DRIP评分的修订版耐药风险评估方案前后的变化。结果显示,方案实施后抗MRSA和抗假单胞菌抗生素使用天数减少,但再入院风险和临床改善时间无显著差异。作者认为,使用临床预测评分的个体化耐药风险评估策略可减少广谱抗生素使用而不增加不良结局。
要点
- 实施基于DRIP评分的风险评估方案后,抗MRSA抗生素使用减少1.44 DOT(P=0.007)。
- 抗假单胞菌抗生素使用减少2.03 DOT(P<0.001)。
- 再入院风险(OR 0.64,95%CI 0.16-2.57)和临床改善时间(HR 1.19,95%CI 0.62-2.21)无显著差异。
核心结论
- 使用临床预测评分对社区起病肺炎进行个体化MDR病原体风险评估,可减少广谱抗生素使用而不增加不良结局。
研究设计与样本
- 回顾性病历审查,纳入102例因社区起病肺炎入院患者,比较实施基于DRIP评分的修订版MDR风险评估方案前后的情况。
- 采用广义线性回归和Cox风险模型进行统计分析。
主要发现
- 方案实施后抗MRSA抗生素使用减少1.44 DOT(P=0.007)。
- 抗假单胞菌抗生素使用减少2.03 DOT(P<0.001)。
- 再入院风险无显著差异(OR 0.64,95%CI 0.16-2.57)。
- 临床改善时间无显著差异(HR 1.19,95%CI 0.62-2.21)。
临床怎么用
- 作者认为,使用临床预测评分进行个体化MDR风险评估的策略可用于减少社区起病肺炎患者广谱抗生素的使用而不增加不良结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is growing evidence that patients with community-onset pneumonia and recent healthcare exposure are not at equally high risk of infection with MDR organisms. An individualized approach is necessary with regard to risk assessment and choice of antibiotics. METHODS: We reviewed the records of 102 patients admitted for community-onset pneumonia, before and after the implementation of a revised risk assessment programme for MDR organisms using the drug resistance in pneumonia (DRIP) score. The primary aim of the study was to identify the effects of this intervention on antibiotic days of therapy (DOT), and secondary outcomes included all-cause readmissions and time to clinical improvement. Statistical analysis was performed using generalized linear regression and Cox hazards models. RESULTS: Implementation of the programme resulted in a decrease in anti-MRSA (-1.44 DOT, P = 0.007) and anti-pseudomonal (-2.03 DOT, P < 0.001) antibiotic utilization, but was not associated with a significant difference in the odds of readmissions (OR 0.64, 95% CI 0.16-2.57) or in time to clinical improvement (HR 1.19, 95% CI 0.62-2.21). CONCLUSIONS: An individualized MDR organism risk assessment strategy using a clinical prediction score for community-onset pneumonia can decrease the utilization of broad-spectrum antibiotics without an increase in adverse outcomes.
引用
- Farkas A, Sassine J, Mathew JP, et al. Outcomes associated with the use of a revised risk assessment strategy to predict antibiotic resistance in community-onset pneumonia: a stewardship perspective. J Antimicrob Chemother. 2018. PMID: 29897465. doi:10.1093/jac/dky202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。